M55 Stock Overview
A clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
MacroGenics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.35 |
| 52 Week High | US$5.05 |
| 52 Week Low | US$0.90 |
| Beta | 2.19 |
| 1 Month Change | 20.77% |
| 3 Month Change | -46.00% |
| 1 Year Change | -69.00% |
| 3 Year Change | -66.44% |
| 5 Year Change | -94.13% |
| Change since IPO | -92.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| M55 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -8.4% | 0.2% | 0.9% |
| 1Y | -69.0% | -11.8% | 13.2% |
Return vs Industry: M55 underperformed the German Biotechs industry which returned -12.1% over the past year.
Return vs Market: M55 underperformed the German Market which returned 13.2% over the past year.
Price Volatility
| M55 volatility | |
|---|---|
| M55 Average Weekly Movement | 14.6% |
| Biotechs Industry Average Movement | 5.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: M55's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: M55's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 341 | Scott Koenig | www.macrogenics.com |
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs.
MacroGenics, Inc. Fundamentals Summary
| M55 fundamental statistics | |
|---|---|
| Market cap | €80.17m |
| Earnings (TTM) | -€59.51m |
| Revenue (TTM) | €133.26m |
0.6x
P/S Ratio-1.3x
P/E RatioIs M55 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| M55 income statement (TTM) | |
|---|---|
| Revenue | US$149.96m |
| Cost of Revenue | US$189.49m |
| Gross Profit | -US$39.53m |
| Other Expenses | US$27.44m |
| Earnings | -US$66.97m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 13, 2025
| Earnings per share (EPS) | -1.06 |
| Gross Margin | -26.36% |
| Net Profit Margin | -44.66% |
| Debt/Equity Ratio | 0% |
How did M55 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/11 16:47 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MacroGenics, Inc. is covered by 19 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Stephen V. Byrne | BofA Global Research |
| Silvan Tuerkcan | Citizens JMP Securities, LLC |